Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System

September 18, 2017 — Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its QMAPP hemodynamic monitoring system.

The QMAPP amplifier is the size of a ream of A4 paper, features all available vital patient monitoring parameters and has up to 32 bipolar intra-cardiac channels for electrophysiology procedures. QMAPP is suitable for today’s hybrid rooms, but also for combined and dedicated cardiac catheterization labs, according to Fysicon. The system is fanless, which minimizes the risk of cross-contamination. The hardware design of QMAPP ensures a high level of usability. The unit is connected via one single cable to the floor base of the X-ray table and with a clamp mounted to the DIN-Rail. The acquired vitals and reporting entries can easily be exchanged with any electronic medical record (EMR) system using standard protocols like DICOM and HL7.

For more information: www.fysicon.com